ライフサイエンスコーパス: administered subcutaneously

1 more efficient than mRNA nanoparticles when administered subcutaneously.

2 cterium bovis bacillus Calmette-Guerin (BCG) administered subcutaneously.

3 From course 2 onward, HDI maintenance was administered subcutaneously.

4 cental growth factor with high affinity, was administered subcutaneously.

5 5-AC is rapidly absorbed and eliminated when administered subcutaneously.

6 th infectious H. pylori when the vaccine was administered subcutaneously.

7 a in both hotplate and tail-flick tests when administered subcutaneously.

8 ment of seasonal allergic rhinitis is 300 mg administered subcutaneously.

9 n=11) or saline (n=10) at a dose of 10 mg/kg administered subcutaneously 24-h after stroke and daily

10 wth and development factor (PEG-rHuMGDF) was administered subcutaneously (25 microg/kg twice weekly f

11 al trial of 16 weeks of 250 microg of GM-CSF administered subcutaneously 3 times/week, followed by op

12 eatment was stabilized with morphine, 30 mg, administered subcutaneously 4 times daily.

13 evelopment factor (PEG-rHuMGDF) or a placebo administered subcutaneously after completion of chemothe

14 When administered subcutaneously, ALN-AT3 showed potent, dose

15 irus (HCV) infection is interferon, which is administered subcutaneously and can have troublesome sid

16 the kidney and inhibit miR-21 function when administered subcutaneously and evaluated the therapeuti

17 s with RAD (everolimus) (0.075 mg/kg per day administered subcutaneously) and FTY720 (0.3 mg/kg per d

18 ee or four doses of 2.5 mg/kg MPTP free base administered subcutaneously at 2-h intervals.

19 Thymosin alpha 1 was administered subcutaneously at 400 microgram/m2 after fo

20 KL was administered subcutaneously at 50 microg/kg, 21 hours an

21 Etanercept was administered subcutaneously at a dose of 0.4 mg/kg (maxi

22 ha was performed using etanercept, which was administered subcutaneously at a dose of 0.5 mg/kg aroun

23 rhIL-12 was initially administered subcutaneously at a dose of 100 ng/kg, wher

24 ultiple sclerosis to compare daclizumab HYP, administered subcutaneously at a dose of 150 mg every 4

25 Etanercept was administered subcutaneously at a dose of 25 mg twice wee

26 5 mg twice daily for 30 days, or enoxaparin, administered subcutaneously at a dose of 40 mg once dail

27 5-AZA was administered subcutaneously at a fixed dose of 75 mg/m(2

28 Erenumab administered subcutaneously at a monthly dose of 70 mg o

29 Both antipsychotics were administered subcutaneously at behaviorally effective do

30 AM0010 was self-administered subcutaneously at doses of 1 to 40 mug/kg o

31 GI2 synthase inhibitor, tranylcypromine, was administered subcutaneously at the time of CLP and again

32 Tildrakizumab was administered subcutaneously at weeks 0 and 4 during part

33 enoceptor antagonist propranolol (2.0 mg/kg) administered subcutaneously before retention testing did

34 nts also received filgrastim 5 micrograms/kg administered subcutaneously beginning on day 2 and conti

35 og of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women daily.

36 The MTD of rhuCD40L when administered subcutaneously daily for 5 days was defined

37 ge colony-stimulating factor 250 microg/m(2) administered subcutaneously daily.

38 GM-CSF (250 mug/m2/d) or placebo were administered subcutaneously (double-blinded) 3 times/wk

39 Five vaccinations were administered subcutaneously during 26 weeks with an addi

40 one (25 mg/kg of body weight) or vehicle was administered subcutaneously during resuscitation.

41 effects of benralizumab (at a dose of 30 mg administered subcutaneously either every 4 weeks or ever

42 ative properties of linezolid and vancomycin administered subcutaneously every 12 hours.

43 Omalizumab was administered subcutaneously every 2 or 4 weeks based on

44 ase, double-blind study of alirocumab 150 mg administered subcutaneously every 2 weeks to 13 patients

45 40 mg, according to body weight) or placebo, administered subcutaneously every 2 weeks.

46 Denosumab was administered subcutaneously every 4 weeks (30, 120, or 1

47 b (at a dose of 100 mg) with that of placebo administered subcutaneously every 4 weeks for 20 weeks.

48 kg lebrikizumab (n = 13) or placebo (n = 16) administered subcutaneously every 4 weeks over 12 weeks,

49 Omalizumab 300 mg administered subcutaneously every 4 weeks reduced weekly

50 Golimumab, administered subcutaneously every 4 weeks, has been show

51 to receive 300 mg of mepolizumab or placebo, administered subcutaneously every 4 weeks, plus standard

52 o AMG 145 350 mg, AMG 145 420 mg, or placebo-administered subcutaneously every 4 weeks.

53 AMG145 or placebo was administered subcutaneously every 4 weeks.

54 Golimumab orplacebo was administered subcutaneously every 4 weeks.

55 to receive either denosumab 60 mg or placebo administered subcutaneously every 6 months in 58 trial c

56 imumab at a dosage of 20 mg, 40 mg, or 80 mg administered subcutaneously every other week to long-ter

57 al antibody therapy targeted to PCSK9 may be administered subcutaneously every two or four weeks.

58 Omalizumab or placebo was administered subcutaneously for 16 weeks, with oral immu

59 f IL-2 from 62,500 to 250,000 IU/m2/day were administered subcutaneously for 6 months to 16 HIV+ indi

60 RhML was administered subcutaneously for 8 weeks to three normal

61 PIXY321 was administered subcutaneously in 2 divided doses.

62 performed a dose-escalation study of MVA-BN administered subcutaneously in 2 doses, one on day 0 and

63 The GM-CSF was administered subcutaneously in 28-day cycles, such that

64 ice a day [200 mg], n = 46), which were self-administered subcutaneously in 28-day treatment periods.

65 MTX was administered subcutaneously in 66 patients (67%).

66 us toxoid (TT) or diphtheria toxoid (DT) and administered subcutaneously in Alhydrogel with or withou

67 c)-D4Aph(Ac)-Leu-ILys-Pro-DAla-NH2] (6) when administered subcutaneously in castrated male rats at a

68 s proof of concept for a monoclonal antibody administered subcutaneously in HIV-1 infected individual

69 sulin peptides B:9-23 and B:13-23, even when administered subcutaneously in the absence of adjuvant,

70 , 75 mug, or 100 mug per day of rhPTH(1-84), administered subcutaneously in the outpatient setting, i

71 San Jose, CA) loaded with 9-cis retinal was administered subcutaneously into Rpe65(-/-) mouse pups f

72 Drugs were administered subcutaneously, LY235959 at doses of 0.5, 1

73 Administered subcutaneously, [N(epsilon)-palmitoyl Lys(B

74 d fashion to receive octreotide (100 microg, administered subcutaneously on day 1, followed by depot

75 nsplants with two 30-mg doses of alemtuzumab administered subcutaneously on days 0 and 1.

76 ltured in the presence of F573, and F573 was administered subcutaneously on days 0 to 5 posttransplan

77 REGN727 doses of 50, 100, or 150 mg were administered subcutaneously on days 1, 29, and 43.

78 CMVPepVax was administered subcutaneously on days 28 and 56.

79 Antibiotics were administered subcutaneously once daily at 12 mg/kg, for

80 wice daily (104), adalimumab at a 40-mg dose administered subcutaneously once every 2 weeks (106), pl

81 Low-molecular-weight heparins administered subcutaneously once or twice daily have bee

82 d gout were randomized to receive rilonacept administered subcutaneously once per week (loading dose

83 -mediated tumor burden in C57BL/6J mice when administered subcutaneously or orally.

84 ered intramyocardially), 5 mg/kg of AMD3100 (administered subcutaneously), or both; cardiac function

85 y occlusion model in rats, clomethiazole was administered subcutaneously over 22.75 h using osmotic m

86 DHEA was administered subcutaneously prior to arthritis induction

87 ecombinant human erythropoietin (epoetin) is administered subcutaneously rather than intravenously, a

88 by 3 orders of magnitude when the strain was administered subcutaneously (s.c.).

89 ranging from 1.0 x 10(3) to 1.0 x 10(5) PFU administered subcutaneously (s.c.).

90 Filgrastim (5 micrograms/kg/d) was administered subcutaneously (SC) beginning on day 2 of e

91 It can be administered subcutaneously (SCIT) or sublingually (SLIT

92 lizing formulation and were more active when administered subcutaneously than orally, both of which s

93 regimen followed by IFN-alpha-2b 10 MIU/m(2) administered subcutaneously three times per week for 48

94 ombined with IFN (6 or 9 million units [MU]) administered subcutaneously three times per week.

95 A whole-cell T. vaginalis vaccine was administered subcutaneously to BALB/c mice, using a prim

96 G-CSF or 5% dextrose in water was administered subcutaneously to cirrhotic and control rat

97 olycaspase inhibitor IDN-1965 or vehicle was administered subcutaneously to Galpha(q) mice by osmotic

98 AV513 administered subcutaneously to low-FVIII dogs for multip

99 with a Ribi- or saponin-type adjuvant, were administered subcutaneously to mice.

100 When administered subcutaneously to NOD mice, this peptide de

101 V-B phototherapy, 16 mg of afamelanotide was administered subcutaneously to the combination therapy g

102 eceive inactivated-poliovirus vaccine (IPV), administered subcutaneously; trivalent OPV manufactured

103 Recombinant leptin was administered subcutaneously twice a day for four months

104 lating factor (G-CSF; 250 microg/kg/day) was administered subcutaneously twice daily on days 3 to 6 a

105 kilogram of body weight) or matching placebo administered subcutaneously twice daily, from 3 days bef

106 weight heparin) per kilogram of body weight, administered subcutaneously twice daily, or continuous i

107 IL-12 was administered subcutaneously twice weekly at doses from 1

108 s received etanercept (0.4 mg/kg) or placebo administered subcutaneously twice weekly for 6 months.

109 Atacicept administered subcutaneously was well tolerated and demon

110 indings also that indicate PIV5-RSV F may be administered subcutaneously, which is the preferred rout

111 ivery system, tailored for lymphatic uptake, administered subcutaneously, will have decreased drug re

112 avenously, but is much better tolerated when administered subcutaneously without loss of therapeutic